MAPT and Alzheimer disease: We leveraged the Anti-Amyloid Treatment in Asymptomatic AD (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) amyloid PET screening dataset of 4486 CU [30, 35] along with the tau PET substudy [29, 30] that included 392 Aβ+ CU individuals with tau PET.